Post-osimertinib landscape for NSCLC
Автор: VJOncology
Загружено: 2025-01-30
Просмотров: 101
Описание:
Alexander Spira, MD, PhD, Virginia Cancer Specialist, Fairfax, VA, comments on the complexity of the post-osimertinib space in non-small cell lung cancer (NSCLC), noting the resurgence of other drugs and the development of new targeted therapies, including antibody-drug conjugates (ADCs) such as patritumab deruxtecan and bispecific antibodies, as well as ongoing studies targeting C797S resistance. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
